More on AKTS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $16.08 |
|
|||
| Open | $16.08 | ||||
| 52 Wk High | $5.77 | ||||
| 52 Wk Low | $1.51 | ||||
| Day High | $16.08 | ||||
| Day Low | $16.08 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 19 | ||||
- Aktis Oncology starts second phase 1b trial for AKY-2519 in lung cancer
- Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
- Oppenheimer Starts Aktis Oncology (AKTS) at Outperform
- Wedbush Starts Aktis Oncology (AKTS) at Outperform
- BMO Capital Starts Aktis Oncology (AKTS) at Outperform
- Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
- Leerink Assumes Aktis Oncology (AKTS) at Outperform
- Aktis Oncology (AKTS) PT Raised to $33 at JPMorgan
- Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)
- Akoustis Technologies (AKTS) PT Raised to $35 at H.C. Wainwright
Entities mentioned with AKTS
- Definitive Agreement | View Related Stories »
- Roth Capital | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- S3 | View Related Stories »
- Show More...
